PolyPid (NasdaqCM:PYPD) 2026 Conference Transcript

Summary of PolyPid Conference Call Company Overview - Company: PolyPid (NasdaqCM:PYPD) - Product: D-PLEX100, a drug designed to deliver 30 days of antibiotic coverage in surgical sites, particularly for colorectal surgeries Key Points NDA Submission and FDA Interaction - PolyPid is preparing for an NDA submission for D-PLEX100, expected to be announced shortly, with a rolling submission plan in place [2][3][13] - The product has received Breakthrough Therapy designation, allowing for more frequent communication with the FDA [5] - The FDA agreed that the Phase 3 SHIELD I study data is sufficient for NDA approval, confirming alignment on efficacy and safety [6] Clinical Data and Efficacy - Top-line data from the Phase 3 trial showed a 60% reduction in surgical site infections (SSI) for patients undergoing colorectal resection, with a p-value of less than 0.005 [2][34] - The study included 1,000 patients, with a primary endpoint showing a 40% reduction in mortality, reoperation, and SSI [34] - Secondary endpoints also demonstrated significant reductions in infection severity, as measured by the ASEPSIS score [34] Market Opportunity - The U.S. market for abdominal surgeries is approximately 4.4 million procedures annually, with significant potential for D-PLEX100 to be used in various surgical contexts beyond colorectal procedures [53] - The product is expected to initially receive a colorectal label, with potential for expansion to other abdominal surgeries, such as breast mastectomy and abdominoplasty [49][50] Launch and Commercialization Strategy - PolyPid is focusing on partnerships with companies that have strong hospital and surgical suite presence to facilitate product adoption [69] - The company is conducting market research and engaging with pharmacy directors and surgeons to prepare for product launch [62][63] - The product is eligible for the New Technology Add-on Payment (NTAP), which may drive adoption [67] Platform Technology - The PLEX platform allows for a unique drug delivery system with thousands of layers, providing localized antibiotic exposure while minimizing systemic effects [84] - Future developments include a long-acting GLP-1 program aimed at metabolic health, which is currently in preclinical stages [85][95] Conclusion - PolyPid is on track for significant milestones with D-PLEX100, including NDA submission and potential market expansion, supported by robust clinical data and a strategic commercialization plan [2][3][13][49]